We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agreement for Large-Scale Genotyping Studies
News

Agreement for Large-Scale Genotyping Studies

Agreement for Large-Scale Genotyping Studies
News

Agreement for Large-Scale Genotyping Studies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agreement for Large-Scale Genotyping Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK). 

Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium™ assays to conduct genetic studies for thousands of samples provided by GSK. 

The blanket agreement enables multiple projects to be conducted over period of time. 

Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies. 

Advertisement